Article Text

PDF
Letters
Sildenafil in bronchopulmonary dysplasia: safe to use?
  1. Andrew James Wardle1,
  2. Georgia May Connolly2,
  3. Tom Stonier3,
  4. Robert Tulloh4
  1. 1Department of Paediatrics, Imperial College, London, UK
  2. 2Department of Paediatrics, Bristol Royal Hospital for Children, Bristol, UK
  3. 3North West Thames Foundation School, London, UK
  4. 4Department of Cardiology, Bristol Royal Hospital for Children, Bristol, UK
  1. Correspondence to Professor Robert Tulloh, Department of Cardiology, Bristol Royal Hospital for Children, Research Floor Level 7, Queens Building, Bristol Royal Infirmary, Bristol BS2 8HW, UK; Robert.Tulloh{at}Bristol.ac.uk

Statistics from Altmetric.com

One-third of preterm infants are diagnosed with bronchopulmonary dysplasia (BPD), a complex multifactorial disorder associated with significant morbidity. Associated pathologies include pulmonary hypertension (PH), a critical cardiorespiratory pathology with 48% 2-year mortality that affects up to a third of infants with BPD.1 Pulmonary vasodilatation in PH prolongs life, and phosphodiesterase-V inhibition is the primary approach for this.2 That stated, current evidence is limited to 45 patients across five case series.3 They demonstrate a reduction in overall mortality to 18%, but reservations remain regarding safety and efficacy.

We therefore conducted a retrospective investigation into patients with BPD–PH managed at our centre between August 2008 and July …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.